1	Application of diagnostic network optimization in Kenya and Nepal
2	to design integrated, sustainable and efficient bacteriology and
3	antimicrobial resistance surveillance networks
4	
5	Marie Brunetti ^{1*} , Amit Singh ² , Sheilla Chebore ³ , Deepak Gyenwali ⁴ , Nada Malou ¹ , Cecilia
6	Ferreyra ¹ , Tulsi Ram Gompo ⁵ , Jyoti Acharya ⁶ , Nisha Rijal ⁶ , Susan Githii ⁷ , Evelyn
7	Wesangula ⁷ , Heidi Albert ⁸
8	DOI for de
9	¹ FIND, Geneva, Switzerland
10	² FIND, Bangalore, India
11	³ FIND, Nairobi, Kenya
12	⁴ FIND, Kathmandu, Nepal
13	⁵ Central Veterinary Laboratory, Kathmandu, Nepal
14	⁶ National Public Health Laboratory, Kathmandu, Nepal
15	⁷ National Antimicrobial Stewardship Interagency Committee, Nairobi, Kenya
16	Corresponding author:
17	marie.brunetti@finddx.org (MB)
18	

- 19 Short title (70 characters): Designing optimized bacteriology and AMR networks in Kenya
- 20 and Nepal
- 21
- 22

see manuscript Dol for details

23 Abstract

24 Antimicrobial resistance (AMR) is a major global public health concern, particularly in low-25 and middle-income countries (LMICs), which experience the highest burden of AMR. Critical 26 to combatting AMR is ensuring there are effective, accessible diagnostic networks in place to 27 diagnose, monitor and prevent AMR, but many LMICs lack such networks. Consequently, there 28 is substantial need for approaches that can inform the design of efficient AMR laboratory 29 networks and sample referral systems in LMICs. Diagnostic network optimization (DNO) is a geospatial network analytics approach to plan diagnostic networks and ensure greatest access to 30 and coverage of services, while maximizing the overall efficiency of the system. In this study, 31 DNO was applied to strengthen bacteriology and AMR surveillance network design in Kenya 32 33 and Nepal for human and animal health, by informing linkages between health facilities and 34 bacteriology testing services, and planning of sample referral routes between farms, health 35 facilities and laboratories. Data collected from the target settings in each country were entered 36 into the open-access DNO tool OptiDx, to generate baseline scenarios, which depicted the 37 current state of AMR laboratory networks and sample referral systems in the countries. 38 Subsequently, the baselines were adjusted to evaluate changing factors such as samples flows, 39 transport frequency, transport costs, and service distances. Country stakeholders then compared 40 resulting future scenarios to identify the most feasible solution for their context. The DNO 41 analyses enabled a wealth of insights that will facilitate strengthening of AMR laboratory and 42 surveillance networks in both countries. Overall, the project highlights the benefits of using a 43 data-driven approach for designing efficient diagnostic networks, to ensure better health 44 resource allocation while maximizing the impact and equity of health interventions. Given the

3

- 45 critical need to strengthen AMR laboratory and surveillance capacity, DNO should be
- 46 considered an integral part of diagnostic strategic planning in the future.
- 47 Abstract word count: 300/300
- 48
- Keywords: diagnostics, laboratory network, antimicrobial resistance, bacteriology 49
- 50 surveillance, diagnostic network optimization, sample referral system

see manuscript DOI for details

51 Introduction

52	Antimicrobial resistance (AMR) is a major global public health concern and growing rates of
53	drug resistance threaten our ability to treat even common infections (1). Drug-resistant
54	infections impose huge costs on individuals and society as they spread between the
55	environment, animals and humans (1, 2). A recent landmark study on the global burden of
56	AMR found that drug-resistant bacteria directly caused 1.27 million deaths and were associated
57	with a further 4.95 million deaths in 2019 (3). It has been estimated that up to 10 million people
58	each year will die as a result of AMR by 2050 unless urgent action is taken (2).
59	The burden of AMR is particularly high in low- and middle-income countries (LMICs), as a
60	result of complex, interplaying factors. LMICs experience a high burden of infectious diseases,
61	but may lack adequate health systems, laboratory capacity, and the resources required for
62	surveillance of such diseases and diagnostic testing to inform appropriate antimicrobial use (3-
63	8). As a result, antibiotic misuse is high in LMICs, where most antibiotic prescriptions are made
64	by doctors and other medical professionals based on empirical diagnosis, without using a
65	diagnostic tool to confirm the underlying infectious agent (9, 10). Consequently, AMR is
66	further driven by the overuse of antibiotics, which encourages the spread of drug-resistant
67	bacteria. Confounding factors, such as poverty, overcrowding and improper handling of
68	contaminated waste in the environment can further contribute to AMR (8). Tackling AMR in
69	LMICs is therefore part of a wider challenge related to health and diagnostic system
70	strengthening.

There are numerous tests to identify infectious agents such as bacteria and fungi and test their
susceptibility to different antimicrobial agents. Common methods include Gram staining,

73 culture, biochemical testing and manual antimicrobial susceptibility testing (AST) (11). More 74 modern methods include testing on automated platforms such as the VITEK system, and 75 genomic sequencing (12). However, in many countries these complex devices may only be 76 available at higher tiers of the healthcare network (e.g. at a central laboratory), or may not be 77 available at all in lower-resource settings (13). This is a particular issue in severe and life-78 threatening conditions like sepsis, where the availability of diagnostics is critical, as the risk of 79 death for the patient increases by an estimated 7.6% with every hour that passes before 80 treatment begins (14).

As a result, laboratory networks and sample referral systems (SRSs) between national, regional, 81 and peripheral facilities are critical for ensuring accessible and timely diagnostic testing. 82 83 Efficient and accessible diagnostic laboratories and SRSs at the lower levels of the health 84 system are particularly important for patient care, as healthcare practitioners require timely 85 results from the identification of pathogen and AST to effectively treat patients with the right 86 antimicrobial agent. Such networks are also vital for AMR surveillance, for example, to 87 monitor community outbreaks of multidrug-resistant bacteria and inform disease control 88 activities and treatment prescribing guidelines at a local level. AMR surveillance is typically 89 conducted using bacterial isolates sent via SRSs to higher levels of the network. However, 90 many LMICs do not have organized SRSs for bacteriology testing and AMR surveillance, and 91 patients may be referred to higher levels of the health system to access these services. When 92 they exist, SRSs often are fragmented and not integrated across diseases. In some cases, there 93 may be no access to suitable laboratories for testing.

94 Strengthening the capacity for bacteriology testing and AMR surveillance in LMICs therefore
95 requires key changes to how testing is handled at all levels of the health system and the

6

96	implementation of a One Health approach that recognizes the interconnection between people,
97	animals, plants, and their shared environment (15). Firstly, there is a critical need for rapid
98	diagnostic solutions in primary care, simplified blood culture methods and AST at higher levels
99	of the network, as well as digital solutions to improve result interpretation and support clinical
100	decisions. Secondly, there is a need to improve access to and optimize the use of existing tests
101	in healthcare systems for both animal and human health. In particular, there is a need for
102	systematic approaches to inform the placement and use of diagnostic instruments, human
103	resources and sample referral linkages.
104	Diagnostic network optimization (DNO) is a geospatial network analytics approach to plan
105	diagnostic networks consistent with national health goals and strategies (13, 16). DNO enables
106	analysis of the current diagnostic network and the development of evidence-based
107	recommendations around the optimal type, number and location of diagnostics and an
108	associated sample referral network that maximize access to and the overall efficiency of the
109	health system (13). DNO is being increasingly used in the public health sector to inform
110	diagnostic instrument placement, optimize sample transportation and referral mechanisms,
111	facilitate geographical prioritization and efficient integration of testing to meet the priority
112	needs of a disease programme (13, 17-21). To date, DNO has largely been used to optimize
113	diagnostic networks for patient management.
114	This study applied DNO to the design of surveillance networks in two LMICs – Kenya and
115	Nepal – looking to strengthen and optimize their diagnostic networks for AMR. Specifically,
116	DNO modelling was used to inform the optimal design of AMR laboratory and sample referral

117 networks in both countries, to improve the coverage and efficiency of AMR surveillance. Here,

- 118 we outline the process used to conduct the DNO analysis and key insights generated from this
- 119 novel application of DNO to diagnostic networks for AMR.

120

Methods 121

- 122 In this study, DNO analyses were conducted in Kenva and Nepal between July 2021 and March
- 123 2022 to inform the design of bacteriology and AMR surveillance networks. DNO was
- 124 conducted in line with established methodology (13) and according to each country's context
- and objectives. The study aimed to optimize linkages between health facilities and bacteriology 125
- testing services at different levels of the health system and assist with the planning of routes for 126

referring samples and isolates between farms, health facilities and laboratories. 127 see ma

128

Study setting 129

130 Kenya's healthcare system is structured across six tiers, starting with community and primary 131 care, up to primary, secondary and tertiary hospitals (22). Primary and secondary hospitals 132 (Levels 4 and 5) offer a wide range of services and receive high volumes of patients referred 133 from lower-level facilities. Kenya is enrolled in the World Health Organization's Global 134 Antimicrobial Resistance and Use Surveillance System (GLASS) and has five AMR 135 surveillance sites participating in the national surveillance system (23). The existing national 136 AMR surveillance strategy focuses on monitoring trends in bacterial resistance to antibiotics, 137 through a network composed of 14 AMR human health laboratories, including the National 138 Microbiology Reference Laboratory (NMRL), located in 13 counties, with plans for expansion

to all 47 counties (24). Testing is typically done on-site through walk-in or referred patients, as

139

140 bacteriology sample referrals for patient management are not in place and only a few isolate 141 referrals exist. Although Kenya has established diagnostic networks and strategic plans for the 142 management of tuberculosis (TB) and HIV (25, 26), existing SRSs for TB and HIV are 143 complex and fragmented, with varied strategies and implementation approaches across donors 144 and implementing partners. 145 In Nepal, the healthcare system is structured across four tiers, comprising community care 146 delivered by community healthcare workers, primary healthcare centres, secondary healthcare facilities (e.g. district hospitals) and tertiary healthcare facilities (e.g. specialized hospitals) 147 148 (27). The laboratory network in Nepal is tiered, with basic diagnostic services for human health 149 available at most health facilities. Hospital-level facilities may have additional testing capacity, 150 such as instruments for detecting TB drug resistance. Nepal is also enrolled in GLASS and has 151 41 AMR surveillance sites (hospitals with an outpatient department and/or inpatient 152 department), participating in the national surveillance system (23). AMR surveillance in the 153 country started in 1999 with a limited number of participant laboratories and organisms under 154 surveillance (28). The programme has since expanded to a network of 25 human health 155 laboratories plus the National Public Health Laboratory (NPHL) in 2022, covering all seven 156 provinces of the country and seven animal health laboratories located in six provinces. 157 Surveillance networks for human and animal health in the country are separate. Through their 158 respective networks, the NPHL and the Central Veterinary Laboratory (CVL) monitor AMR 159 among the possible isolates from patients and animals, respectively, through confirmatory 160 testing and quality assurance. Currently, Nepal lacks an organized referral system for 161 bacteriology testing and AMR surveillance. As specimens are not always referred, farmers and

- 162 patients directly submit specimens to the nearest laboratory using their own transport system
- 163 and testing is done on-site. Referral of bacterial isolates for confirmatory testing at NPHL and
- 164 CVL is also not commonly practiced. However, Nepal has started to establish active
- 165 surveillance in the animal health sector to strengthen the One Health approach in AMR
- 166 surveillance and response (29), which this project will assist with planning and implementing.
- 167

Objectives and expected outcomes 168

168	Objectives and expected outcomes
169	The main objectives of the DNO analysis were to:
170	1. estimate projected future demand for bacteriology and AST testing and determine the
171	optimal capacity and placement of diagnostics to meet future needs in a cost-efficient
172	manner; see

- 173 2. use established country diagnostic networks to model future expansion of referring
- facilities within the network; and 174
- 175 3. develop optimal sample transport mechanisms for isolates referred from sentinel sites to 176 national reference laboratories to maximize surveillance coverage.
- 177

DNO tool: OptiDx 178

179 The DNO analysis was conducted using OptiDx, a web-based, open-access network analytic

- 180 tool, designed for use in LMICs (30). OptiDx models the impact of simultaneously changing
- 181 multiple parameters of network design and performance so multiple scenarios can be compared

- 182 and evaluated. OptiDx is currently in use across LMICs to support DNO analysis for various
- 183 diseases including COVID-19, HIV, TB and human papillomavirus.

184

DNO process 185

A DNO analysis typically comprises five key steps (13). An overview of the process followed 186

×

- 187 in Kenya and Nepal for each key step is outlined in Table 1.
- 188
- details Table 1. Key components of DNO process undertaken in Kenya and Nepal 189

Step	Details
Define scope 500	• Define scope of analysis in Kenya and Nepal in
	collaboration with key stakeholders
Collate and prepare data	Identify data sources
	• Develop template for data collection
	• Collate and clean data
Conduct baseline analysis of	Conduct baseline analysis of diagnostic networks for
diagnostic network for	human health, device footprint, testing capacity and
animal and human health to	referral linkages
determine the existing	
routing, current demand,	

device placement and	• In Nepal, conduct baseline analysis of diagnostic networks
frequency of isolate referrals	for animal health, existing device footprint, testing
	capacity and referral linkages
	• Man available country data on testing and overlay with the
	avisting network to understand gaps and opportunities for
	existing network to understand gaps and opportunities for
	improved coverage and efficiency of the network, and
	referral integration
Run customized optimization	• Estimate the growth in testing demand and assess
scenarios based on current	scenarios to meet the projected demand using the available
testing and plans for active	device footprint and potential procurement of additional
surveillance and compare	devices
satisfies and comparently to	devices
network outputs	• Project future demand for bacteriology and confirmatory
	testing and recommend optimal referral design, including
	options for integration into existing networks for other
	samples, transport modes, costs and resource estimates
	• Compare expected impact of various network designs and
	instances expected impact of various network designs and
	implementation strategies
Select outputs for	• Establish national datasets and dynamic network models
implementation and to	for human and animal health that can be interrogated for
support decision-making	future scenarios for bacteriology and antimicrobial
	susceptibility testing

• Use model outputs to inform national action plans and
implementation planning
• Support the development of tools/documents on outputs of
the DNO exercise to inform cost and design of sample
referral systems, including integrated referral systems

190

1. Scope of analysis 191

- In both countries, DNO analyses were initiated in 2021, which was considered the "baseline" 192
- 193
- 194

for the AMR and bacteriology networks. Kenya In Kenya, the scope of the DNO analysis was defined in collaboration with the National 195 196 Antimicrobial Stewardship Interagency Committee (NASIC) and key stakeholders to ensure 197 alignment with the priority needs of the country. Kenya's Ministry of Health requested that the 198 analysis focus on AMR networks for human health only. Stakeholders agreed that the analysis 199 would focus on including AMR within the integrated SRS, which is currently being 200 implemented in the country. As such, the DNO analysis focused on 13 counties with an AMR 201 sentinel surveillance site (shown in Fig. 1a) and covered testing for bacteriology/AMR, TB and 202 HIV. AMR sentinel surveillance sites are usually a hospital laboratory, which can collect 203 specimens, conduct testing and transport isolates to the NMRL and report surveillance data 204 based on AST conducted. Specific tests included in the analysis were: Gram stain, culture, 205 bacterial identification, AST, and quality assurance/confirmatory testing for bacteriology/AMR 206 at NMRL; GeneXpert MTB/RIF and culture/drug susceptibility testing for TB; and early infant

diagnosis for HIV. Previous DNO work conducted with Kenya's National TB Programme wasalso used to inform the current project (31).

209

210 Nepal

211 In Nepal, discussions were initiated with government authorities and stakeholders to introduce 212 DNO and OptiDx and understand priorities for AMR surveillance. The most important need 213 identified was to strengthen and institutionalize the referral linkages between sentinel sites and reference laboratories to improve AMR surveillance in human and animal health. Available 214 data on AMR testing and surveillance in Nepal were reviewed to inform the development of a 215 216 quantified scope of work for the DNO analysis. For animal health, it was agreed that the analysis would include culture, bacterial identification, and AST on samples from poultry 217 218 species across the geographical scope shown in Fig 1b. For animal health, five out of the seven 219 veterinary laboratories were included, as the two remaining veterinary sentinel sites did not 220 share any data, and 331 farms and slaughterhouses were mapped to those testing sites. 221 For human health, it was agreed that the DNO analysis would cover Bagmati province with its 222 10 AMR human health sentinel sites (Fig 1c). In addition to the bacteriology/AMR programme, 223 the analysis also considered sample referrals for TB and HIV in humans. Specific tests included 224 in the analysis were: Gram stain, culture, bacterial identification, AST, bacterial re-225 identification, confirmatory testing for bacteriology/AMR; GeneXpert MTB/RIF for TB; and 226 viral load testing for HIV. 227

228 Fig 1. Geographical scope of DNO analysis

- 229 a) in Kenya for human health
- 230 **b)** in Nepal for animal health
- 231 c) in Nepal for human health
- 232

2. Collation and preparation of data for analysis 233

- 234 In Kenya and Nepal, data templates were developed to collect information and key metrics to
- 235 help evaluate existing bacteriology sample referral and AMR surveillance networks, as of 2021.
- Table 2 outlines the key data that were collected for Kenya and Nepal. Multiple data sources 236
- were used to map the 2021 baseline network, including literature review documentation, 237

programmatic reports and laboratory datasets. 238 see ma

239

240
Table 2. Key data collected to inform DNO analyses in Kenya and Nepal

KENYA	NEPAL	
	Animal health	Human health
14 sites in 13 counties	5 sites in 4 provinces	10 sites in 1 province
 Routes, frequency and transport modes used for TB/HIV sample referrals Locations of microbiology laboratories and TB/HIV testing sites (geocoordinates) 	 Locations of farms (no geocoordinates, information at ward level) Locations of veterinary laboratories (geocoordinates) 	 Routes, frequency, and transport modes used for TB/HIV samples referrals Locations of microbiology laboratories (geocoordinates)

Human resource capacity	Human resource capacity	Human resource capacity
in microbiology	in veterinary laboratories	in microbiology
laboratories (list and	(list and number of staff	laboratories (list and
number of staff engaged in	engaged in diagnostic and	number of staff engaged in
diagnostic and AST	AST testing)	diagnostic and AST
testing)	 Bacteriology and AST 	testing)
 Bacteriology and AST 	tests performed (culture,	 Bacteriology and AST
tests performed (culture,	identification, AST, etc.)	tests performed (culture,
identification, AST, etc.)	• Existing testing capacity at	identification, AST, etc.)
 Existing testing capacity at microbiology laboratories (number of devices, tests performed on each device, etc.) Transport costs 	 Existing testing capacity at veterinary laboratories (number of devices, tests performed on each device, etc.) Transport costs 	 Existing testing capacity at microbiology laboratories (number of devices, tests performed on each device, etc.) Transport costs
• Transport costs SO	• Test costs	• Test costs
• Test costs		

241 AMR, antimicrobial resistance; AST, antimicrobial susceptibility testing; TB, tuberculosis.

242

In Nepal, there were substantial challenges with data availability and quality, notably the nonavailability of the geocoordinates for health facilities and farms. Geocoordinates of the human health facilities were manually collected using Google Maps, while fictive locations of farms were created using the geographic information system QGIS. The geographic information system (GIS) file of ward distribution was imported into QGIS software to get ward surface areas and coordinates, and a number of farms were assigned to each ward using the random points inside polygon function. Farms were then placed at the centroid of the ward in urban

250	municipalities, and randomly distributed within the ward in rural municipalities. Those farm
251	locations were then converted to geocoordinates and imported into OptiDx for analysis.

252

3. Building of baseline model

The data collected in step 2 were entered into OptiDx to map current bacteriology diagnostic and AMR surveillance networks in Kenya and Nepal (as of 2021). The baseline analyses gave a geographical representation of the diagnostic networks and helped determine the existing routing, current testing demand, device placement and frequency of isolate referrals for human health in Kenya and for human health and animal health in Nepal. Findings from the baseline assessment were presented to the respective partners in Kenya and Nepal for feedback to help inform the design of future optimized scenarios and future analyses as the networks evolve.

261

262 4. Development of customized optimization scenarios

Based on the baseline analyses and feedback collected from partners, optimization scenarios
were created using OptiDx. In the optimized scenarios, current bacteriology and AMR networks
were overlayed with existing TB/HIV referral systems to identify gaps and opportunities for
specimen referrals and integration across diseases in both countries. Several optimized referral
networks were modelled, for samples and isolates referred between farms/health facilities,
AMR sentinel sites and national reference microbiology laboratories, and then compared based
on costs associated with the deployment of the different SRS designs.

270

5. Selection and implementation of DNO outputs

272 Final DNO outputs were presented to the respective Ministries of Health and stakeholders in 273 Kenva and Nepal. Outputs were evaluated to determine the most efficient sample referrals 274 through integrating needs for bacteriology/AMR SRSs with existing systems established for 275 other diseases. DNO allowed stakeholders in Kenya and Nepal to adjust inputs and constraints 276 and weigh up different elements of each scenario to identify the preferred solution for their 277 context. Based on the outputs, a practical guide was developed to support Nepal with setting up 278 and implementing a referral system for the surveillance of human AMR. In Kenya, the recommended county referral systems will be used for the establishment of sample referrals 279 280 between selected sites and AMR laboratories, and will support the Referral System Technical Working Group in negotiations with contracting courier services to provide sample referral 281 282 services for all specimens. The integrated sample referral system in Kenya is being 283 implemented at the county level by implementing partners and the counties. Detailed transport 284 costings were also created to support these interventions.

285 **Results**

Key insights from baseline and optimal network designs for AMR in Kenya and Nepal aredescribed here.

288

289 Kenya

290 Baseline

291	Between January and December 2021, a total of 100,294 bacteriology and antimicrobial
292	susceptibility tests in the 14 AMR human health laboratories were conducted in Kenya. Gram
293	stain and culture testing accounted for 71% of the total demand for bacteriology testing. Around
294	80% of the total AMR testing volume in Kenya was undertaken by just three out of the 14
295	laboratories (Moi Teaching Hospital in Uasin Gishu, Kenyatta National Hospital in Nairobi and
296	Machakos Hospital in Machakos). The overall average device utilization was low (6%) and
297	varied from 1% to 24% across sites. Across devices, CO2 incubators had the highest utilization
298	rates (17.5%). MALDI-TOF, which is present only at NMRL and one surveillance site, had low
299	utilization (1.2%), as did the automated blood culture devices that are available in most
300	surveillance sites (1.5%). Key reasons for low device utilization and demand were unserviced
301	equipment, a lack of staff training, and high facility workload.
302	Across the 13 AMR surveillance sites in the network in 2021, six of them sent isolates to the
303	NMRL for quality assurance and confirmatory testing during Q1 to Q3 2021 via the courier
304	drop-off sites (G4S, shown in orange lanes in S1 Fig). The overall volume of isolates sent at
305	baseline was low (64 isolates) but is already increasing as AMR surveillance expands and
306	isolate referrals and shipments to NMRL become a common practice across all sentinel sites.

307

308 Future state scenarios & recommendations

In Kenya, 89 Level 4 and 5 hospitals across 13 counties were identified as health facility
candidates to be linked with the AMR sentinel sites for sample transportation for patient
management. Most hospitals are already connected to the AMR sites, which are county or subcounty referral hospitals, through samples referred for rapid TB or HIV molecular testing

313	conducted at AMR sites, or through samples that are pooled at AMR sites and further
314	transported to a testing site. Additionally, some AMR sites are already connected to the NMRL
315	through sample referrals for TB culture and drug susceptibility testing (depicted in S2 Fig),
316	allowing for bacteriology sample and isolate referrals to be integrated into the pre-existing
317	services supported by TB/HIV programmes and partners.
318	Fig 2 and Table 3 show a comparison of the four optimized scenarios recommended by the
319	DNO analysis for the first tier of the network (referral of patient samples from health facilities
320	to the AMR site), in terms of annual distance, transport costs and number of routes required.
321	The integration of AMR samples with the TB/HIV SRS (scenario 4) was found to optimize the
322	efficiency of the network. Annually, the integration of AMR with the existing TB/HIV SRS
323	would save an average of 210,726 km travelled and US\$ 44,481. Consequently, when possible,
324	the DNO analysis strongly recommended that referrals with pre-existing SRSs are integrated to
325	ensure sustainability and cost savings.
326	
327	Fig 2. Annual distance, transport cost and number of routes required across optimized scenarios
328	for the first tier of network in Kenya (sample referrals from health facilities to AMR sites)
329	
330	
331	AMR, antimicrobial resistance; EID, early infant diagnosis of HIV; TB, tuberculosis; VL, viral load.
332	
333	Table 3. Distance and cost savings across optimized scenarios for the first tier of network in

- 334 Kenya (sample referrals from health facilities to AMR sites)

2	2	5
2	2	J

First tier of network:	Scenario 1	Scenario 2	Scenario 3	Scenario 4
Health facility to AMR site	No	Partial	Partial	Integration with
linkages	integration	integration with	integration with	existing TB/HIV
		existing HIV VL	existing TB	referrals
		& EID referrals	GeneXpert	
			referrals	
Percentage of integrated	0%	39%	55%	76%
routes				
Annual distance saved (km)	0	104,716	157,677	210,726
Percentage of annual	0%	30%	44%	59%
distance saved			or dere	
Annual transport cost saved	0	\$22,708	\$32,810	\$44,481
(US\$)	1150	ripi		
Percentage of annual	0%	31%	44%	60%
transport cost saved				

336 AMR, antimicrobial resistance; EID, early infant diagnosis of HIV; TB, tuberculosis; VL, viral load.

337

An example of the recommended SRS for the first tier of the network (sample movements
between the hospitals and AMR sentinel sites) is shown in Fig 3 and S1 Table. In the optimized
scenario for Bungoma County, Naitiri Sub-County Hospital is linked to the nearest AMR site,
which is Kitale County Referral Hospital in Trans Nzoia County. The optimized scenario
creates opportunities for transport cost savings through using existing TB and HIV referrals.

344

345

346 Fig 3. Recommended bacteriology sample referral system in Bungoma County

347

348

349	Fig 4 and Table 4 show a comparison of the optimized scenarios recommended by the DNO
350	analysis for isolate transportation to NMRL in terms of annual distance, transport costs and
351	number of routes required. Findings from the analysis indicated that the optimal SRS for the
352	second tier of the network – isolate transportation to NMRL from ARM sentinel sites – would
353	be through using the current referral system for TB culture and drug susceptibility testing,
354	which is already in place for 8 AMR sites (S3 Fig). Assuming a transport frequency of twice a
355	month, this scenario (scenario 2 in Fig 4 and Table 5) would result in annual transport cost
356	savings of US\$ 8711. manua
357	SEO
358	Fig 4. Annual distance, transport cost and number of routes required across optimized scenarios
359	for the second tier of network in Kenya (AMR isolate referrals to the National Microbiology
360	Reference Laboratory)
361	
362	AMR, antimicrobial resistance; C/DST, culture/drug susceptibility testing; NMRL, National Microbiology
363	Reference Laboratory; TB, tuberculosis.
364	
365	Table 4. Distance and cost savings across optimized scenarios for the second tier of network in

366 Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)

Second tier of network: AMR site to	Scenario 1	Scenario 2
NMRL linkages	No integration	Partial integration with existing
		TB C/DST referrals
Percentage of integrated routes	0%	62%
Annual distance saved (km)	0	39,596
Percentage of annual distance saved	0	53%
Annual transport cost saved (US\$)	0	\$8711
Percentage of annual transport cost saved	0%	53%

367 ript DOI for details AMR, antimicrobial resistance; C/DST, culture/drug susceptibility testing; NMRL, National Microbiology

Reference Laboratory; TB, tuberculosis. 368

369

A costing analysis was performed to evaluate the cost of implementing the recommended SRSs, 370 371 using data that were provided by the county authorities and assumptions defined with NASIC 372 on a number of elements (including transport modes, distance travelled, transport frequency, 373 referral routes). When estimating the cost of moving samples from point A to B and excluding 374 other cost elements such as human resources, packaging, supplies and documentation, the 375 estimated annual transport cost was US\$ 73,987 for the first tier of the network and US\$ 16,580 376 for the second tier (S3 Table).

377

Nepal: animal health 378

Baseline 379

380 Between January and December 2021, a total of 3549 bacteriology and AST tests on faecal,

381 caecal and tissue samples from poultry species in five laboratories were conducted in Nepal;

382	42% of these were culture tests, 25% were bacterial identification tests and 33% were AST
383	tests. A large proportion of bacteriology testing for animal health in Nepal came from one site,
384	the CVL, which conducted 43% of overall bacteriology testing in the poultry population. Two
385	sites - the CVL and National Avian Disease Investigation Laboratory - were found to
386	undertake almost 70% of the overall testing volume for poultry species in Nepal. However,
387	CVL was found to receive few isolates (around 10 on an annual basis) from veterinary
388	laboratories each year for confirmatory testing due to a lack of mechanisms for referral,
389	resources, and staff training.
390	Future state scenarios & recommendations
391	As Nepal is embarking on active surveillance for the poultry population, the creation of a hub-
392	spoke model for animal health in Nepal was recommended for connecting farms and
393	slaughterhouses to regional veterinary laboratories to limit the distance travelled by farmers. In
394	the model, hubs (samples collection points) are located at local municipality government offices
395	to leverage the presence of veterinary technicians who could be responsible for collecting the
396	samples and transporting them to the testing laboratory. Examples of the recommended hub and
397	spoke SRS for the entire network and for Janakpur laboratory are shown in Fig 5.
398	
399	Fig 5. Recommended sample referral system for animal health in Nepal
400	a) Hub-spoke model for Nepal overall
401	

402 CVL, Central Veterinary Laboratory; NAL, National Avian Disease Investigation Laboratory.

403

404 **b)** Hub-spoke model for Janakpur laboratory

405

406	The recommended isolate referral system for the second tier of the network is shown in S4 Fig.
407	With only four regional veterinary laboratories in the model and a low estimated number of
408	isolates (n=72) to be sent to the CVL on an annual basis, the recommended isolate referral
409	system could ship specimens once or twice a month using a mix of motorbike and airplane as
410	modes of transportation.
411	A costing analysis was conducted to determine the estimated annual cost associated with the
412	transport of specimens across six scenarios, varying in terms of transport frequency (Table 5).
413	A network model with a maximum allowable distance of 20 km between the farm and hub was
414	also explored. In this model, 63 hubs were necessary instead of the 81 created in the network
415	model where no maximum allowable distance constraint was considered. As there are fewer
416	hubs in the network, the costs are also lower, as seen in Table 5.
417	

418 Table 5. Estimated annual transport cost for the network from hub to regional labs and labs to419 CVL

	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5	Scenario 6
Network linkages	Via hubs	Via hubs	Via hubs	Via hubs	Via hubs	Via hubs
Sample transport	6 times/week	6 times/week	4 times/ week	4 times/week	3 times/week	3 times/week

frequency hub-lab						
Isolate transport frequency lab-CVL	Twice/month	Monthly	Twice/month	Monthly	Twice/month	Monthly
Transport cost (US\$) Transport cost with MAD constraint (US\$)	\$156,531.46 \$120,871.38	\$156,338.65 \$120,678.56	\$104,482.85 \$80,709.46	\$104,290.04 \$80,516.64 For deta	\$78,458.55 \$60,628.51	\$78,265.73 \$60,435.69

420

CVL, Central Veterinary Laboratory; MAD, maximum allowable distance.

421

422

423

424 Nepal: human health

425 **Baseline**

426 Between January and December 2021, 180,404 bacteriology and AST tests were performed in

427 10 laboratories for human health and culture tests accounted for 61% of total bacteriological

428 testing demand. For human health, just two out of 10 human health sentinel sites drove almost

429 half (48 %) of the bacteriology testing. The average utilization across devices was 29%, with

430 significant variations across laboratories (from 3% to 72%).

431 Future state scenarios & recommendations

432	As 15 out of the 21 AMR sentinel sites in Nepal's network for human health are already
433	sending specimens for HIV viral load testing directly to NPHL in Kathmandu, there is the
434	opportunity to leverage existing referrals and add AMR isolates to the shipment to NPHL. The
435	use of intermediate hubs located at the Provincial Public Health Laboratories was also
436	considered so that isolates could be consolidated at a more centralized location within a
437	common province and then transported together to NPHL. In these scenarios, four intermediate
438	hubs serving nine microbiology laboratories were created.
439	Fig 6 and S2 Table show a comparison of the six scenarios created for the second tier of
440	network in Nepal for human health. The hub-spoke model was estimated to be more costly than
441	the integrated transport system (US\$ 3900 versus US\$ 2600 annually) as the total annual
442	distance saved was smaller (37,762 km versus 54,298 km) and number of routes higher (16
443	versus 6). Scenario 3 and 4 with the partial integration with HIV viral load sample referrals
444	allow an annual cost saving of US\$ 1589 compared with scenario 1 (US\$ 4202).
445	
446	Fig 6. Annual distance, transport cost and number of routes required across optimized scenarios
447	for the second tier of network in Nepal for human health (AMR isolate referrals to the National

448 Public Health Laboratory)

449

450 AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL, viral
451 load.

452 The recommended direct-to-lab isolate referral system is shown in Fig 7.

27

453	
454	
455	Fig 7. Recommended bacterial isolate referral system for human health in Nepal:
456	Direct to lab
457	a) Outside Kathmandu Valley
458	b) Kathmandu Valley

459 **Discussion**

460 In this study, the application of DNO created a wealth of insights into the bacteriology and 461 AMR surveillance networks in Kenya and Nepal, and enabled the design of efficient and cost-462 effective diagnostic networks adapted to each country's settings and priorities. Specifically, the 463 analysis highlighted key gaps and opportunities to inform the design of specimen referrals in 464 both countries. Findings from the DNO analysis also provided evidence for establishing 465 optimized sample and isolate referral networks and informed the development of an operational guide for AMR isolate referrals in Nepal. Furthermore, the analyses highlighted the potential 466 for leveraging existing TB/HIV networks for bacteriology sample and isolate referrals in Kenya 467 and Nepal for human health. While DNO has been successfully applied to optimize diagnostic networks for other diseases 468

469 470 like TB and HIV (18, 20, 21), this was the first large-scale application of DNO to AMR. The 471 critically high burden of AMR in LMICs carries dire consequences for the health of people and 472 animals in such settings, as drug-resistant organisms spread throughout the environment and 473 between countries. Strengthening diagnostic networks and surveillance systems is key to 474 tackling growing rates of AMR (3, 5), and as such, DNO offers lower-resource countries an 475 evidence-based, open-access approach to optimize their diagnostic networks. As scaling up 476 surveillance laboratories is a timely and costly endeavour, DNO can help design and optimize 477 specimen/isolate referral systems to increase access to testing and improve surveillance in the 478 shorter term in resource-limited settings.

Findings from the analyses are being used to guide decision-makers in Kenya and Nepal inbudgeting and action planning for the implementation of the recommended referral systems. In

29

481 Kenya, the national SRS technical working group is currently engaging an external provider to 482 provide sample referral services for all specimens, and the DNO outputs will be used to support 483 the design and implementation of the integrated model. In Nepal, the recommended referral 484 network design, proposed route maps and operational guidance will be used to establish a 485 strong and sustained isolate referral network for human health and animal health. The DNO analyses in Kenya and Nepal also provided a number of learnings and considerations 486 487 that can be used to guide future applications of DNO to AMR. Firstly, when working on AMR 488 laboratory networks, it is important to consider that AMR programmes are often relatively new 489 in LMICs compared with other more established national disease programmes like TB and HIV. In this study, DNO was a new concept to the national AMR programmes, which meant 490 491 the benefits of the approach and specific outputs that countries could use had to be communicated clearly to stakeholders who were unfamiliar with the process. 492 493 Early engagement with the country stakeholders was therefore important to align partners on 494 the objectives of and benefits from DNO upfront, and drive engagement with the project. Work 495 was undertaken to highlight the benefits of DNO for the AMR programmes and define scopes 496 for the analyses that took the local context and national priorities into account, to make sure 497 outputs were impactful and useful. Early engagement was also important to identify and address 498 any capacity building needs that stakeholders may have had around conducting a DNO analysis. 499 Building the capacity of the national AMR programmes and key stakeholders around DNO is 500 important to enable an inclusive and country-owned process and ensure that implementable 501 outputs are prioritized during the process. For settings where geospatial analysis is a new 502 concept, an initial laboratory mapping exercise may also be beneficial to secure interest in DNO

and give stakeholders the skills to evaluate network designs and refine questions to be

addressed by the full DNO analysis.

This study also highlights that newer programmes like AMR should utilize data-driven strategic planning to design diagnostic networks as early as possible, to reduce network inefficiencies, avoidable costs, and challenges with access and coverage from the start. Utilizing DNO enables the deployment of diagnostic networks based on need for services rather than geographic or administrative considerations.

510 Another key consideration when conducting any DNO analysis is that the availability and quality of data significantly affect the resources needed and timelines for conducting a DNO, as 511 well as outcomes of the analysis. Therefore, before undertaking any analysis, it is essential to 512 513 ascertain that key data inputs, such as geocoordinates of health facilities and testing sites, are 514 available. In terms of AMR specifically, the nature of bacteriology and AMR networks may 515 also present some challenges compared with other disease-specific diagnostic networks such as 516 TB/HIV. In particular, defining tests, testing capacity, device-test combinations and estimating 517 test costs can be challenging, as bacteriology testing comprises a sequence of different steps 518 than cannot be separated from each other. In addition, an important component of bacteriology 519 and AST testing is manual testing (e.g. culture), which is more difficult to model than machine-520 based testing. Furthermore, as DNO is most effective when embedded in planning/funding 521 cycles, a DNO analysis needs to be conducted at an appropriate time, when insights from the 522 analysis can contribute to the development of evidence-based national strategic plans, funding 523 requests, resource allocation, or procurement and operational planning. 524 Finally, it is important to note that the value and impact of a DNO analysis will ultimately

525 depend on whether the suggested interventions are adopted and how well they are implemented

and monitored. Consequently, plans should be in place to support the practical implementation

527 of interventions and for the monitoring and evaluation of interventions once established.

528 Application of DNO to AMR also presents opportunities to address other potential questions

and topics that may be of interest in the future, including sequencing capacity placement, how

- 530 best to support AMR surveillance efforts, and where diagnostic network capacity for
- 531 bacteriology and AST could be integrated with testing for other diseases to increase access and

532 efficiency.

Limitations of this study largely related to the availability of data for the DNO. In Nepal, the analysis was limited in geographic scope as much of the data need for a countrywide analysis (e.g. geocoordinates, laboratory data) were not available. Some of the approaches utilized to overcome data issues included using approximate farm locations, estimating annual data for 2021 using quarterly/biannual data, and modelling testing capacity. These factors could have affected the precision of the recommended network designs in Nepal, but provided stakeholders with an initial analysis that would have not been available otherwise.

540 Overall, the project highlights the benefits of using a data-driven approach for designing

541 efficient diagnostic networks, to ensure better health resource allocation while maximizing the

542 impact and equity of health interventions. Given the critical need to strengthen AMR laboratory

543 and surveillance capacity, network mapping and optimization should be considered an integral

544 part of diagnostic strategic planning in the future.

81886; this version posted November 5, 2022. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/20 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Acknowledgements 545

546 The authors would like to thank André Trollip, FIND, for his technical support on the AMR 547 laboratory testing and costing, Kinuthia Bubi, FIND, for support with project coordination and 548 administrative support, and Dr Runa Jha and Lilee Shrestha from NPHL Nepal for their support 549 to carry out this study. Medical writing support was provided by Talya Underwood, MPhil, of 550 Anthos Communications Ltd, UK, funded by FIND, according to Good Publication Practice 551 guidelines.

552

553

Data sharing statement script DOI for details 554 The minimal dataset has been uploaded in the Supporting Information files. Data requests should 555 be directed to Dr Tulsi Gompo, Central Veterinary Laboratory, Nepal, (contact via 556 tulsigompo@gmail.com), to Jyoti Acharya, National Public Health Laboratory, Nepal, (contact 557 via jyotigan30@gmail.com), to Dr Evelyn Wesangula, National Antimicrobial Stewardship 558 Interagency Committee, Kenya (contact via wesangulaeva@gmail.com). All other underlying 559 data are provided in the manuscript and/or the Supporting Information files.

560

Funding 561

562 This work was funded by the Department of Health and Social Care's Fleming Fund using UK

563 aid. The views expressed in this publication are those of the authors and not necessarily those of

564 the UK Department of Health and Social Care or its Management Agent, Mott MacDonald.

565

566 **Contributors**

- 567 Conceptualization: Heidi Albert, Cecilia Ferreyra, Nada Malou
- 568 Data curation: Marie Brunetti, Amit Singh
- 569 Formal analysis: Marie Brunetti, Amit Singh, Sheilla Chebore
- 570 Funding acquisition: Heidi Albert, Cecilia Ferreyra
- 571 Investigation: Marie Brunetti, Sheilla Chebore, Deepak Gyenwali, Nisha Rijal, Amit Singh
- 572 Methodology: Heidi Albert, Marie Brunetti, Amit Singh
- 573 Project administration : Heidi Albert, Marie Brunetti, Cecilia Ferreyra, Deepak Gyenwali, Nada
 574 Malou
- 575 Supervision: Heidi Albert, Jyoti Acharya, Cecilia Ferreyra, Susan Githii, Tulsi Gompo, Nada
- 576 Malou, Evelyn Wesangula
- 577 Validation: Heidi Albert, Marie Brunetti, Jyoti Acharya, Susan Githii, Sheilla Chebore, Tulsi
- 578 Gompo, Amit Singh, Evelyn Wesangula
- 579 Visualization: Heidi Albert, Marie Brunetti, Amit Singh
- 580 Writing original draft: Heidi Albert, Marie Brunetti
- 581 Writing review & editing: Heidi Albert, Jyoti Acharya, Marie Brunetti, Sheilla Chebore, Cecilia
- 582 Ferreyra, Susan Githii, Tulsi Gompo, Deepak Gyenwali, Nada Malou, Nisha Rijal, Amit Singh,
- 583 Evelyn Wesangula
- 584

Declaration of interests 585

586 Heidi Albert, Marie Brunetti, Cecilia Ferreyra, Deepak Gyenwali and Amit Singh are employed 587 by FIND, the global alliance for diagnostics. Sheilla Chebore and Nada Malou were consultants 588 for FIND during the project. FIND is a not-for-profit foundation that supports the evaluation of 589 publicly prioritized tuberculosis assays and the implementation of WHO-approved (guidance and prequalification) assays using donor grants. FIND has product evaluation agreements with 590 591 several private sector companies that design diagnostics for tuberculosis and other diseases. - neutrali See manuscript DOI for O These agreements strictly define FIND's independence and neutrality with regard to these private 592 593 sector companies.

594

595

596 **References**

597

598	1	World Health Organization Antim	icrobial resistance 2021	[Available from:
390	1.	wond fiearth Organization. Anthin	liciobial resistance 2021	[Available from.

- 599 https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance.
- 600 2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations:
- 601 Government of the United Kingdom; 2016.
- 602 3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial
- 603 resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55.
- 4. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al.

605 Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered

- 606 picture. Antimicrobial Resistance & Infection Control. 2021;10(1):63.
- 5. Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income
- 608 countries: current status and future directions. Expert Rev Anti Infect Ther. 2022;20(2):147-60.
- 609 6. Yadav H, Shah D, Sayed S, Horton S, Schroeder LF. Availability of essential
- 610 diagnostics in ten low-income and middle-income countries: results from national health
- 611 facility surveys. The Lancet Global Health. 2021;9(11):e1553-e60.
- 612 7. Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in
- 613 Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United
- 614 Republic of Tanzania. Bull World Health Organ. 2017;95(11):738-48.

- 615 8. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of
- 616 Antibiotic Resistance Transmissionin Low- and Middle-Income Countriesfrom a "One Health"
- 617 Perspective-A Review. Antibiotics (Basel). 2020;9(7).
- 618 9. Sulis G, Adam P, Nafade V, Gore G, Daniels B, Daftary A, et al. Antibiotic prescription
- 619 practices in primary care in low- and middle-income countries: A systematic review and meta-
- 620 analysis. PLoS Med. 2020;17(6):e1003139.
- 621 10. Do NTT, Vu HTL, Nguyen CTK, Punpuing S, Khan WA, Gyapong M, et al.
- 622 Community-based antibiotic access and use in six low-income and middle-income countries: a
- 623 mixed-method approach. The Lancet Global Health. 2021;9(5):e610-e9.
- 624 11. Giuliano C, Patel CR, Kale-Pradhan PB. A Guide to Bacterial Culture Identification
 625 And Results Interpretation. Pt. 2019;44(4):192-200.
- CEC II
- 626 12. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al.
- 627 Developmental roadmap for antimicrobial susceptibility testing systems. Nature Reviews
- 628 Microbiology. 2019;17(1):51-62.
- 629 13. FIND. Diagnostic network optimization: A network analytics approach to design
- 630 patient-centred and cost-efficient diagnostic systems 2021 [Available from:
- 631 <u>https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-</u>
- 632 <u>Optimization_15.11.2021.pdf</u>.
- 633 14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of
- 634 hypotension before initiation of effective antimicrobial therapy is the critical determinant of
- 635 survival in human septic shock. Crit Care Med. 2006;34(6):1589-96.

636	15.	World Health Organization	One Health 2017	Available from:
		0		

- 637 https://www.who.int/news-room/questions-and-answers/item/one-health.
- 638 16. Nichols K, Girdwood SJ, Inglis A, Ondoa P, Sy KTL, Benade M, et al. Bringing Data
- 639 Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income
- 640 Countries: Process, Terms and Definitions. Diagnostics (Basel). 2020;11(1).
- Albert H, Purcell R, Wang YY, Kao K, Mareka M, Katz Z, et al. Designing an 641 17.
- 642 optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho.
- PLOS ONE. 2020;15(6):e0233620. 643
- details Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S. 644 18.

645 Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. PLOS ONE. 2019;14(8):e0221586. 646

647 19. Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V, et al. Uganda's

648 New National Laboratory Sample Transport System: A Successful Model for Improving Access

649 to Diagnostic Services for Early Infant HIV Diagnosis and Other Programs. PLOS ONE.

650 2013;8(11):e78609.

651 20. Nichols BE, Girdwood SJ, Crompton T, Stewart-Isherwood L, Berrie L, Chimhamhiwa

652 D, et al. Impact of a borderless sample transport network for scaling up viral load monitoring:

653 results of a geospatial optimization model for Zambia. J Int AIDS Soc. 2018;21(12):e25206.

654 21. Robin TA, Khan MA, Kabir N, Rahaman ST, Karim A, Mannan, II, et al. Using spatial

655 analysis and GIS to improve planning and resource allocation in a rural district of Bangladesh.

- 656 BMJ Glob Health. 2019;4(Suppl 5):e000832.
- 657 22. Republic of Kenya Ministry of Health. Kenya Health Policy 2014–2030. 2014.

- 658 23. World Health Organization. Global Antimicrobial Resistance and Use Surveillance
- 659 System (GLASS) Report: 2021. 2021.
- 660 24. Government of Kenya. National Action Plan for the Prevention and Containment of
- 661 Antimicrobial Resistance. 2017.
- 662 25. Republic of Kenya Ministry of Health. Kenya AIDS Strategic Framework II.
- 663 26. Republic of Kenya Ministry of Health. National Strategic Plan for Tuberculosis,
- 664 Leprosy and Lung Health. 2019.
- 665 27. Adhikari B, Mishra SR, Schwarz R. Transforming Nepal's primary health care delivery
- 666 system in global health era: addressing historical and current implementation challenges.
- 667 Globalization and Health. 2022;18(1):8.
- Acharya KP, Wilson RT. Antimicrobial Resistance in Nepal. Front Med (Lausanne).
 2019;6:105.
- 670 29. The Fleming Fund. A Protocol for Active AMR Surveillance in Poultry. 2019.
- 671 30. OptiDx. OptiDx [Available from: <u>https://www.optidx.org/</u>.
- 672 31. FIND. Optimizing TB diagnostic networks to improve patient access to quality TB
- 673 diagnosis and treatment 2018 [Available from: https://nltp.co.ke/wp-
- 674 content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf.
- 675
- 676
- 677
- 678

679 Supporting information

- 680 **S1 Table.** Recommended bacteriology sample referral system for hospitals in Bungoma County
- 681 **S2 Table.** Distance and cost savings across optimized scenarios for the second tier of network
- in Nepal for human health (AMR isolate referrals to the National Public Health Laboratory)
- 683 AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL,
- 684 viral load.
- 685 **S3 Table.** Distance and cost savings across optimized scenarios for the second tier of network
- in Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)
- 687 S1 Fig. Isolate referrals at baseline in Kenya
- 688 S2 Fig. Baseline sample referral network for human health in Kenya
- 689 S3 Fig. Optimized isolate referral system in Kenya recommended by model
- 690 **S4 Fig.** Recommended animal health sample referral system for isolates in Nepal







Health facility to AMR site linkages







AMR site to NMRL linkages











